Two cases of primary malignant fibrous histiocytoma of the liver: Immunohistochemical expression of ezrin and its relationship with prognosis

Acta Histochemica et Cytochemica

Volumn 42, Issue 3, 2009, Pages 83-88

  Sugitani, Masahiko ^a   Aramaki, Osamu ^a   Kikuchi, Kentaro ^a   Sheikh, Aleemuzzaman ^a   Oinuma, Toshinori ^a   Mamiya, Takao ^a   Takayama, Tadatoshi ^a   Nemoto, Norimichi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Ezrin; Liver; Malignant fibrous histiocytoma; Prognosis

Indexed keywords

EID: 67650647535     PISSN: 00445991     EISSN: 13475800     Source Type: Journal    
DOI: 10.1267/ahc.09002     Document Type: Article

References (25)

1. Akisawa, N., Nishimori, I., Iwamura, T., Onishi, S. and Hollingsworth, M. A. (1999) High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. Biochem. Biophys. Res. Commun. 258; 395-400.
2. Alberti-Flor, J. J., O'Hara, M. F., Weaver, F., Evans, J., McClure, R. and Dunn, G. D. (1985) Malignant fibrous histiocytoma of the liver. Gastroenterology 89; 890-893.
3. Anagnostopoulos, G., Sakorafas, G. H., Grigoriadis, K. and Kostopoulos, P. (2005) Malignant fibrous histiocytoma of the liver: a case report and review of the literature. Mt. Sinai J. Med. 72; 50-52.
4. Chen, H. C., Chen, C. J., Jeng, C. M. and Yang, C. M. (2007) Malignant fibrous histiocytoma presenting as hemoperitoneum mimicking hepatocellular carcinoma rupture. World J. Gastroenterol. 13; 6441-6443.
5. Conran, R. M. and Stocker, J. T. (1985) Malignant fibrous histiocytoma of the liver-a case report. Am. J. Gastroenterol. 80; 813-815.
6. Ding, G. H., Wu, M. C., Yang, J. H., Cheng, S. Q., Li, N., Liu, K., Dai, B. H. and Cong, W. M. (2006) Primary hepatic malignant fibrous histiocytoma mimicking cystadenocarcinoma: a case report. Hepatobiliary Pancreat. Dis. Int. 5; 620-623.
7. Elzagheid, A., Korkeila, E., Bendardaf, R., Buhmeida, A., Heikkilä, S., Vaheri, A., Syrjänen, K., Pyrhönen, S. and Carpén, O. (2008) Intense cytoplasmic ezrin immunoreactivity predicts poor survival in colorectal cancer. Hum. Pathol. 39; 1737-1743.
8. Geiger, K. D., Stoldt, P., Schlote, W. and Derouiche, A. (2000) Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas. Am. J. Pathol. 157; 1785-1793.
9. Ishak, K. G., Goodman, Z. D. and Stocker, J. T. (2001) Malignant mesenchymal tumors. In "Tumors of the Liver and Intrahepatic Bile Ducts. Fascicle 31, Atlas of Tumor Pathology, Third Series", ed. by J. Rosai and L. H. Sobin, Armed Forces Institute of Pathology, Washington DC, pp. 281-230.
10. Khanna, C., Khan, J., Nguyen, P., Prehn, J., Caylor, J., Yeung, C., Trepel, J., Meltzer, P. and Helman, L. (2001) Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res. 61; 3750-3759.
11. Khanna, C., Wan, X., Bose, S., Cassaday, R., Olomu, O., Mendoza, A., Yeung, C., Gorlick, R., Hewitt, S. M. and Helman, L. J. (2004) The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat. Med. 10; 182-186.
12. Köbel, M., Gradhand, E., Zeng, K., Schmitt, W. D., Kriese, K., Lantzsch, T., Wolters, M., Dittmer, J., Strauss, H. G., Thomssen, C. and Hauptmann, S. (2006) Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma. Int. J. Gynecol. Pathol. 25; 121-130.
13. Li, Y. R., Akbari, E., Tretiakova, M. S., Hart, J., Akbari, M., Urbanski, S. J. and Gao, Z. H. (2008) Primary hepatic malignant fibrous histiocytoma: clinicopathologic characteristics and prognostic value of ezrin expression. Am. J. Surg. Pathol. 32; 1144-1158.
14. Mäkitie, T., Carpén, O., Vaheri, A. and Kivelä, T. (2001) Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma. Invest. Ophthalmol. Vis. Sci. 42; 2442-2449.
15. Mhawech-Fauceglia, P., Dulguerov, P., Beck, A., Bonet, M. and Allal, A. S. (2007) Value of ezrin, maspin and nm23-H1 protein expressions in predicting outcome of patients with head and neck squamous-cell carcinoma treated with radical radiotherapy. J. Clin. Pathol. 60; 185-189.
16. Moilanen, J., Lassus, H., Leminen, A., Vaheri, A., Bützow, R. and Carpe ́n, O. (2003) Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients. Gynecol. Oncol. 90; 273-281.
17. O'Brien, J. E. and Stout, A. P. (1964) Malignant fibrous xanthomas. Cancer 17; 1445-1455.
18. Rydholm, A. and Syk, I. (1986) Malignant fibrous histiocytoma of soft tissue. Correlation between clinical variables and histologic malignancy grade. Cancer 57; 2323-2324.
19. Torer, N., Kayaselcuk, F., Nursal, T. Z., Yildirim, S., Tarim, A., Nòyan, T. and Karakayali, H. (2007) Adhesion molecules as prognostic markers in pancreatic adenocarcinoma. J. Surg. Oncol. 96; 419-423.
20. Wakamatsu, D., Tsuyama, S., Maezono, R., Kato, K., Ogata, S., Takao, S., Natsugoe, S., Aikou, T. and Murata, F. (2005) Immunohistochemical detection of the cytoskeletal components in gastric parietal cells. Acta Histochem. Cytochem. 38; 331-337.
21. Weiss, S. W. and Enzinger, F. M. (1978) Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer 41; 2250-2266.
22. Weng, W. H., Ahlén, J., Aström, K., Lui, W. O. and Larsson, C. (2005) Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin. Cancer Res. 11; 6198-6204.
23. Working Group of World Health Organization Classification of Tumors of Soft Tissue and Bone (2002) So-called fibrohistiocytic tumours. In "Pathology and Genetics of Tumors of Soft Tissue and Bone" ed. by C. D. M. Fletcher, K. K. Unni and F. Mertens. International Agency for Research on Cancer Press, Lyon, pp. 109-126.
24. Ye, M. F., Zheng, S., Xu, J. H. and Chen, L. R. (2007) Primary hepatic malignant fibrous histiocytoma: a case report and review of the literature. Histol. Histopathol. 22; 1337-1342.
25. Yu, Y., Khan, J., Khanna, C., Helman, L., Meltzer, P. S. and Merlino, G. (2004) Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat. Med. 10; 175-181.